NVS/MNTA’s Lovenox=44% of total scripts/46% of new scripts, according to the latest IMS data cited by a report from Cowen this morning. NVS/MNTA are closing in on the 50% market share one would expect in a “pure” duopoly with pricing parity and unfettered supply.